Comprehensive Whole‐Course Management Strategy for Recurrent Renal Cell Carcinoma: Case Report and Literature Review
PengNan Hu, Di Chen, Jun Yu, Hua Mi
TL;DR
This paper presents a treatment strategy for recurrent kidney cancer using a combination of PD-1 inhibitors and Axitinib.
Contribution
The paper introduces a novel treatment approach combining PD-1 inhibitors with Axitinib for recurrent renal cell carcinoma.
Findings
PD-1 inhibitors combined with Axitinib may be more effective than Axitinib alone in managing tumor metastasis.
The proposed strategy offers an efficacious treatment option for recurrent renal cell carcinoma.
Abstract
Renal cell carcinoma, a highly recurrent and metastatic malignancy. Drawing upon a decade‐long expertise in managing recurrent cases, we advocate the adoption of Programmed Death‐1 (PD‐1) inhibitors in conjunction with Axitinib when monotherapy with Axitinib fails to restrain tumor metastasis, thereby empowering doctors with an efficacious treatment option.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRenal cell carcinoma treatment · Renal and related cancers · Cancer Immunotherapy and Biomarkers